SELLAS Shares Surge After Phase 3 Leukemia Vaccine Cuts Death Risk by 41%
SELLAS Life Sciences stock jumped sharply on Tuesday after its cancer vaccine met the primary overall survival goal in a pivotal Phase 3 trial for acute myeloid leukemia patients






